Vapi, Gujarat-based fermentation manufacturer of Rifamycin pharma intermediates and APIs for anti-TB drugs
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 7 | 7 | 7 | 7 | 7 | 11 | 11 | 11 |
| Reserves | 35 | 63 | 96 | 142 | 194 | 237 | 254 | 277 |
| Borrowings | 8 | 5 | 1 | 0 | 3 | 30 | 71 | 162 |
| Other Liabilities | 14 | 14 | 18 | 17 | 17 | 22 | 41 | 54 |
| Total Liabilities | 64 | 88 | 122 | 166 | 221 | 301 | 377 | 503 |
| AssetsFixed Assets | 17 | 19 | 19 | 33 | 38 | 41 | 162 | 289 |
| CWIP | 0 | 2 | 13 | 21 | 91 | 184 | 132 | 121 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 47 | 67 | 90 | 113 | 92 | 76 | 82 | 93 |
| Total Assets | 64 | 88 | 122 | 166 | 221 | 301 | 377 | 503 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 1 | 1 | 11 | 40 | 39 | 64 | 91 | 49 |
| Cash from Investing | -6 | -3 | -2 | -30 | -20 | -55 | -112 | -172 |
| Cash from Financing | 5 | 2 | -5 | -14 | -13 | -9 | 26 | 115 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | -5 | -3 | 7 | 26 | 16 | -10 | -25 | -124 |
| FCF Margin | — | — | — | — | — | — | — | — |
For capital-heavy businesses (telecom, power, heavy manufacturing) reported profit ignores the cash needed just to stand still. We'd systematically overvalue it, so we don't show a number.
GUJTHEM · CAPITAL_INTENSIVE
Guides on how to read this kind of business and the numbers that matter.